Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Tolerability of Donanemab in Indian Participants With Early Symptomatic Alzheimer's Disease

NCT07838155 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07838155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07838155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Tolerability of Donanemab in Indian Participants With Early Symptomatic Alzheimer's Disease
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
July 31, 2030
Enrollment
50 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease